Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight

被引：546

作者：

Ho, Terence C. S. ^{[1
]}

Chan, Alex H. Y. ^{[1
]}

Ganesan, A. ^{[1
]}

机构：

[1] Univ East Anglia, Sch Pharm, Norwich NR4 7TJ, Norfolk, England

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2020年 / 63卷 / 21期

关键词：

D O I：

10.1021/acs.jmedchem.0c00830

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clinical development for oncology as well as other therapeutic indications. This Perspective reviews the biological and medicinal chemistry advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.

引用

页码：12460 / 12484

页数：25

共 167 条

[1] Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies [J].

Abaza, Yasmin M. ;

Kadia, Tapan M. ;

Jabbour, Elias J. ;

Konopleva, Marina Y. ;

Borthakur, Gautam ;

Ferrajoli, Alessandra ;

Estrov, Zeev ;

Wierda, William G. ;

Alfonso, Ana ;

Chong, Toh Han ;

Chuah, Charles ;

Koh, Liang-Piu ;

Goh, Boon-Cher ;

Chang, Julie E. ;

Durkes, Daniel E. ;

Foudray, Maria Cielo ;

Kantarjian, Hagop M. ;

Dong, Xiao Qin ;

Garcia-Manero, Guillermo .

CANCER, 2017, 123 (24) :4851-4859

[2] The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets [J].

Abramson, Hanley N. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (09) :611-627

[3] Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies [J].

Aggarwal, Rahul ;

Thomas, Scott ;

Pawlowska, Nela ;

Bartelink, Imke ;

Grabowsky, Jennifer ;

Jahan, Thierry ;

Cripps, Amy ;

Harb, Armand ;

Leng, Jim ;

Reinert, Anne ;

Mastroserio, Ilaria ;

Thach-Giao Truong ;

Ryan, Charles J. ;

Munster, Pamela N. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (11) :1231-1239

[4] HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine [J].

Aramsangtienchai, Pornpun ;

Spiegelman, Nicole A. ;

He, Bin ;

Miller, Seth P. ;

Dai, Lunzhi ;

Zhao, Yingming ;

Lin, Hening .

ACS CHEMICAL BIOLOGY, 2016, 11 (10) :2685-2692

[5] JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity [J].

Arts, Janine ;

King, Peter ;

Marien, Ann ;

Floren, Wim ;

Belien, Ann ;

Janssen, Lut ;

Pilatte, Isabelle ;

Roux, Bruno ;

Decrane, Laurence ;

Gilissen, Ron ;

Hickson, Ian ;

Vreys, Veronique ;

Cox, Eugene ;

Bol, Kees ;

Talloen, Willem ;

Goris, Ilse ;

Andries, Luc ;

Du Jardin, Marc ;

Janicot, Michel ;

Page, Martin ;

van Emelen, Kristof ;

Angibaud, Patrick .

CLINICAL CANCER RESEARCH, 2009, 15 (22) :6841-6851

[6] Recent advances in class IIa histone deacetylases research [J].

Asfaha, Yodita ;

Schrenk, Christian ;

Avelar, Leandro A. Alves ;

Hamacher, Alexandra ;

Pflieger, Marc ;

Kassack, Matthias U. ;

Kurz, Thomas .

BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (22)

[7]

Atadja P, 2016, SUCCESSFUL DRUG DISC, P59, DOI DOI 10.1002/9783527800315.CH4

[8]

Azevedo Cristina, 2015, Advances in Biological Regulation, V60, P144, DOI 10.1016/j.jbior.2015.09.008

[9] A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas [J].

Balasubramanian, S. ;

Ramos, J. ;

Luo, W. ;

Sirisawad, M. ;

Verner, E. ;

Buggy, J. J. .

LEUKEMIA, 2008, 22 (05) :1026-1034

[10] Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview [J].

Banerjee, Suvankar ;

Adhikari, Nilanjan ;

Amin, Sk Abdul ;

Jha, Tarun .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 164 :214-240

← 1 2 3 4 5 6 7 8 9 10 →